|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | 动脉粥样硬化血栓形成门诊患者1年内心血管事件的发生率显示文摘背景:目前,有关社区中动脉粥样硬化血栓形成稳定患者心血管(cardiovascular,CV)事件发生率的资料比较少,既往也无国际性队列研究对冠状动脉病(coronary artery disease,CAD)、脑血管病(cerebrovascular disease,CVD)、外周动脉病(peripheral arterial disease,PAD)确诊患者以及此类疾病高危患者不同事件的发生率进行评估。
目的:在患有动脉疾病的门诊患者或存在多个动脉粥样硬化血栓形成危险因素的门诊患者中确定当今世界1年内CV事件的发生率。
设计、地点及参试者:“减少动脉粥样硬化血栓形成维系健康(Reduction of Artherotllrombosis for Continued Health,REACH)”注册研究是一项国际前瞻性队列研究。研究人员于2003—2004年从44个国家、5587名医生入选68236例已确诊的动脉粥样硬化性血管病患者(CAD、PAD、CVD;n=55814)以及至少存在3个动脉粥样硬化血栓形成危险因素的患者(n=12422)。
主要观测指标:CV死亡、心肌梗死(myocardial infarction,MI)及卒中的发生率。结果:截至2006年7月,共有95.22%的患者(n=64977)提供了1年内的结局。心血管死亡、MI及卒中的总体发生率为4.24%;动脉粥样硬化性血管病患者为4.69%,仅存在多个危险因素的患者为2.15%。CAD、CVD及PAD患者CV死亡、MI及卒中的总体发生率分别为4.52%、6.47%和5.35%。CAD、CVD及PAD患者发生终点事件(即CV死亡、MI、卒中)以及因动脉粥样硬化血栓形成事件入院的几率分别为15.20%、14.53%和21.14%。上述事件发生率随症状性动脉疾病病变部位数量的增加而增加,仅存在危险因素的患者为5.31%,有1处症状性动脉疾病的患者为12.58%,有2处症状性动脉疾病的患者为21.14%,有3处症状性动脉疾病的患者为26.27%(趋势P〈0.001)。
结论:在这项当代大型国际研究中,患有动脉粥样硬化性血管病的门诊患者以及有动脉粥样硬化血栓形成危险的门诊患者CV事件的年发生率相对较高。存在多部位病变者CV事件的1年发生率升高。 | Gabriel Steg Deepak L. Bhatt Peter W. F. Wilson Ralph D' Agostino E. Magnus Ohman Joachim Roether Chiau-Suong Liau Alan T. Hirsch Jean-Louis Mas Yasuo Ikeda Michael J. Pencina Shinya Goto 徐成斌(译) 李呈亿(校) | 2007 | 美国医学会杂志(中文版)2007，26，4： | 20 |
| 2 | 比伐卢定对行经皮冠状动脉介入的急性冠状动脉综合征患者的作用:ACUITY试验的一项亚组分析 | Stone G.W. White H.D. Ohman E.M. 杜媛 | 2007 | 世界核心医学期刊文摘(心脏病学分册)2007，0，8： | 6 |
| 3 | 世界各地动脉粥样硬化血栓形成门诊患者心血管危险因素的流行及诊治情况显示文摘背景:动脉粥样硬化血栓形成是导致心血管疾病和死亡的主要原因。至今,尚无国际数据库阐述动脉粥样硬化血栓形成患者动脉硬化危险因素的特征和治疗强度。
目的:确定动脉粥样硬化危险因素的发生及治疗在世界许多国家是否具有可比性。设计、地点及参试者:“降低动脉粥样硬化血栓形成保持健康研究”(Reduction of Atherothrombosis for Continued Health,REACH)搜集了动脉粥样硬化危险因素及治疗情况的数据。从2003年到2004年,44个国家、5473位内科从业医师总共发现67888例年龄≥45岁的动脉病患者(冠心病[coronaryartery disease,CAD],n=40258;脑血管病,n=18843;周围动脉病,n=8273)或≥3个动脉粥样硬化血栓形成危险因素(n=12389)。主要观测指标:动脉粥样硬化危险因素的基线发生率、药物应用情况及危险因素控制程度。结果:全世界动脉粥样硬化血栓形成患者具有相似的危险因素,即高血压(81.8%)、高胆固醇血症(72.4%)以及糖尿病(44.3%)的比例高。超重(39.8%)、肥胖(26.6%)以及病态肥胖(3.6%)的发生率在大部分地区相似,但是以北美最高(超重:37.1%,肥胖:36.5%,病态肥胖:5.8%;与其他地区比较P〈0.001)。患者采用他汀(总共69.4%;范围:从脑血管病的56.4%到CAD的76.2%)、抗血小板治疗(总共78.6%;范围:从≥3个危险因素的53.9%到CAD的85.6%)及其他循证(降低危险)普遍不足。确诊有血管病的患者在吸烟者为数可观(14.4%)。高血压病治疗不足(基线50.0%血压升高)、高血糖诊断不足(4.9%)以及空腹血糖受损(其中36.5%不知已有糖尿病)均很常见。在有症状的动脉粥样硬化血栓形成患者中,15.9%是有症状的多血管疾病患者。
结论:这项当代大型国际数据库研究显示,在世界许多地区典型心血管危险因素的发生是一致且常见的,但是大多治疗不足、控制不得力。 | Deepak L. Bhatt, MD P. Gabriel Steg, MD E. Magnus Ohman, MD Alan T. Hirsch, MD Yasuo Ikeda, MD Jean-Louis Mas, MD Shinya Goto, MD Chlau-Suong Liau, MD, PhD Alain J. Richard, MD, PhD Joachim Roether, MD Peter W. F. Wilson, MD 徐成斌(译) | 2007 | 美国医学会杂志(中文版)2007，26，1： | 5 |
| 4 | 全球动脉粥样硬化血栓形成门诊患者中心血管危险因素的患病率、认知和治疗显示文摘Context: Atherothrombosis is the leading cause of cardiovascular morbidity and mortality around the globe. To date, no single international database has characterized the atherosclerosis risk factor profile or treatment intensity of individuals with atherothrombosis. Objective: To determine whether atherosclerosis risk factor prevalence and treatment would demonstrate comparable patterns in many countries around the world. Design, Setting, and Participants: The Reduction of Atherothrombosis for Continued Health(REACH) Registry collected data on atherosclerosis risk factors and treatment. A total of 67 888 patients aged 45 years or older from 5473 physician practices in 44 countries had either established arterial disease(coronary artery disease[CAD], n=40 258; cerebrovascular disease, n=18843; peripheral arterial disease, n=8273) or 3 or more risk factors for atherothrombosis(n=12 389) between 2003 and 2004. Main Outcome Measures: Baseline prevalence of atherosclerosis risk factors, medication use, and degree of risk factor control. Results: Atherothrombotic patients throughout the world had similar risk factor profiles: a high proportion with hypertension(81.8% ), hypercholesterolemia(72.4% ), and diabetes(44.3% ). The prevalence of overweight(39.8% ), obesity(26.6% ), and morbid obesity(3.6% ) were similar in most geographic locales, but was highest in North America(overweight: 37.1% , obese: 36.5% , and morbidly obese: 5.8% ; P< .001 vs other regions). Patients were generally undertreated with statins(69.4% overall; range: 56.4% for cerebrovascular disease to 76.2% for CAD), antiplatelet agents(78.6% overall; range: 53.9% for ≥ 3 risk factors to 85.6% for CAD), and other evidence-based risk reduction therapies. Current tobacco use in patients with established vascular disease was substantial(14.4% ). Undertreated hypertension(50.0% with elevated blood pressure at baseline), undiagnosed hyperglycemia(4.9% ), and impaired fasting glucose(36.5% in those not known to be diabetic) were common. Among those with symptomatic atherothrombosis, 15.9% had symptomatic polyvascular disease. Conclusion: This large, international, contemporary database shows that classic cardiovascular risk factors are consistent and common but are largely undertreated and undercontrolled in many regions of the world. | Bhatt D.L Gabriel Steg P Magnus Ohman E. 黄浙勇 | 2006 | 世界核心医学期刊文摘(心脏病学分册)2006，2，5： | 5 |
| 5 | 在接受治疗的急性冠状动脉综合征患者中,肌钙蛋白峰值与长期缺血事件之间的关系显示文摘非ST段抬高急性冠状动脉综合征(acutecoro-narysyndromes,ACS)患者肌钙蛋白水平与结局的关系虽然已经明确,但接受抗血小板治疗管理的非ST段抬高ACS患者肌钙蛋白水平与长期结局的关系尚未明确。 | 刘莉 叶鹏 Goldstein SA Newby LK Cyr DD Neely M Lüscher TF Brown EB White HD Ohman EM Roe MT Hamm CW | 2017 | 中华高血压杂志2017，25，5： | 2 |
| 6 | Antithrombotic therapy dur ing percutaneous coronary intervention: the Seventh ACCP Conference on Antithromhotic and Thrombolytic Therapy显示文摘 | Popma JJ Berger P Ohman EM | 2004 | Chest2004，126，3： | 1 |
| 7 | Alginate production affects Pseudomonas aeruginosa biofilm development and architecture, but is not essential for biofilm formation显示文摘 | Stapper AP Narasimhan G Ohman DE | 2004 | J Med Microbiol2004，53，： | 1 |
| 8 | In-hospital mortality associated with the use of intra-aortic balloon counterpulsation显示文摘 | Freedman RJ Ohman EM | 2004 | Am J Cardiol2004，94，2： | 1 |
| 9 | Wound infections after cardiac surgery-a wound scoring system may improve early detection 显示文摘 | Tegnell A Aren C Ohman L | 2002 | Scand Cardiovasc J2002，36，1： | 1 |
| 10 | Troponin:an important prognostic marker and risk-stratification tool in non-ST-segment elevation acute coronary syncdromes显示文摘 | Newby LK Goldmann BU Ohman EM | 2003 | J Am Coll Cardiol2003，41，4： | 1 |
| 11 | Long - term effects of lifestyle behavior change in coronary artery disease:effects on recurrent corenaryevents after percutaneous coronary intervention 显示文摘 | Lisspers J Sundin O Ohman A | 2005 | Health Psyehol2005，24，1： | 1 |
| 12 | Vascular and neural dysfunction in Zucker diabetic fatty rats: a difficult condition to reverse 显示文摘 | Ohman CL Davidson EP Coppey LJ | 2008 | Diabetes Obes Metab2008，10，1： | 1 |
| 13 | Role of an alginate lyase for alginate transport in mucoid Pseudomonas aeruginosa显示文摘 | Jain S Ohman DE | 2005 | Infection and Immunity2005，73，10： | 1 |
| 14 | Identification of the antigenic epltopes in staphylococcal enterotoxins A and E and design of a superantigen for human cancer therapy显示文摘 | Sjoberg A Wallen - Ohman M Antonsson P | 2003 | Mol Biol2003，333，5： | 1 |
| 15 | Hospital performance and differences by kidney function in the use of recommended therapies after non-ST-elevation acute coronary syndromes显示文摘 | Patel UD Ou FS Ohman EM | | 0，，03： | 1 |
| 16 | Prasugrel versus clopidogrel for patients with unstable angina or non-ST-segment elevation myocardial infarction with or without angiography:a secondary,prespecified analysis of the TRILOGY ACS trial显示文摘 | Wiviott S D White H D Ohman E M | 2013 | Lancet2013，382，9892： | 1 |
| 17 | Antithrombotic therapy in patients undergoing percutaneous coronary intervention 显示文摘 | Popma JJ Ohman EM Weitz J | 2001 | Chest2001，119，1： | 1 |
| 18 | A new antibody recognizing the Ⅷ mutation of human epidermal growth factor receptor显示文摘 | Ohman L | 2002 | Tumor Biol2002，23，： | 1 |
| 19 | Predicting bed agglomeration tendencies for biomass fuels fired in FBC boilers: a comparison of three different prediction methods显示文摘 | Skrifvars B J Ohman M Nordin A | 1999 | Energy & Fuels1999，13，2： | 1 |
| 20 | Preliminary experience with intravenous P2 Y12 platelet receptor inhibiti on as an adjunct to reduced-dose alteplase during acute myocardial infarction: results of the Safety, Tolerability and Effect on Patency in Acute Myocardial Infarction (STEP-AMI) angiographic trial 显示文摘 | Greenbaum AB Ohman EM Gibson CM | 2007 | Am Heart J2007，154，4： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员